CorMedix Inc. — Key Metrics
13 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)↑+271193.5% +$2K
$2K
Book Value Per Share↑+302611.9% +$5K
$5K
Free Cash Flow Per Share↑+358993.5% +$2K
$2K
Cash Per Share↑+127309.6% +$2K
$2K
Revenue Per Share↑+76568930.4% +$4K
$4K
OCF Per Share↑+388184.4% +$2K
$2K
Return on Equity↑+119.3pts
66.6%
Return on Assets↑+82.2pts
34.5%
Return on Invested Capital↑+104.7pts
61.3%
Current Ratio↓-83.1% -$10
2.11
Quick Ratio↓-84.4% -$10
1.94
Asset Turnover↑+20329.2% +$1
0.66
Days Sales Outstanding↑+131.2% +$114
200.51
Days Payables Outstanding↓-97.6% -$5K
130.28
Days Inventory On Hand↑+6561.0% +$484
491.03
Cash Conversion Cycle↑+110.5% +$6K
561.26
R&D / Revenue↓-6872.0pts
6.2%
SBC / Revenue↓-2636.6pts
4.4%
Capex / Revenue↓-745.8pts
0.7%
Working Capital↑+215.4% +$132M
$193M
Net Current Asset Value↓-189.2% -$114M
$-54M
Invested Capital↑+545.4% +$343M
$405M
OCF / Net Income↑+43.2% +$0
1.07
FCF / Net Income↑+32.4% +$0
1.06
Accruals Ratio (Sloan)↑+8.8pts
-1.5%
Net Debt↓-126.9% -$83M
$-149M
Net Debt / EBITDA↓-144.2% -$3
-0.98
Interest Coverage↑+102.9% +$2K
53.97
Cash Coverage↑+104.7% +$1K
62.92
Capex Coverage↑+621.8% +$92
77.45
Tangible Common Equity↓-106.0% -$67M
$-4M
TCE / Total Assets↓-91.5pts
-0.5%
Goodwill / Total Assets
3.6%
NOPAT↑+745.6% +$173M
$150M
Cash ROIC↑+112.7pts
70.5%
WC / Revenue↓-31950.8pts
61.8%
Capex / D&A↓-85.5% -$20
3.34
Reinvestment Rate↑+211.2pts
206.5%
Asset Growth vs Revenue Growth↓-81.9pts
-21.9%
Revenue 5Y CAGR↑+322.9pts
319.7%
Book Value 5Y CAGR↑+27.1pts
55.7%
Stock Price (FY-end)↑+155.6% +$7
$12
Market Cap↓-99.5% -$170M
$934K
P/E Ratio
0.01
P/S Ratio↓-100.0% -$898
0.00
P/B Ratio↓-99.9% -$3
0.00
P/TB Ratio
0.01
P/OCF Ratio
0.01
P/FCF Ratio
0.01
Enterprise Value↓-239.4% -$254M
$-148M
EV / EBITDA
-0.98
EV / Sales↓-100.1% -$555
-0.47
EV / FCF
-0.85
FCF Yield↑+18513.1pts
18499.9%
Shareholder Yield↓-1478.0pts
-1481.0%
R&D Yield↑+2062.3pts
2070.0%
Capex Yield↑+241.1pts
242.0%
Graham Number
$15K
Shares Variation (YoY)
36.4%
Beta (5Y)↓-19.0% -$0
1.08
Cost of Equity↓-1.3pts
9.9%
52W High↓-5.8% -$1
$17
52W Low↑+31.4% +$1
$6
Trailing Return 1Y↑+80.4pts
41.7%
Trailing Return 5Y↑+80.6pts
37.5%
F-Score (Piotroski)↑+25.0% +$1
5.00
Z-Score (Altman)↓-91.6% -$10
0.96
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.